OVERVIEW

Changes in pharmacovigilance activities in and outside Europe have prompted new challenges for all stakeholders. Methodologies used in risk management are evolving and becoming increasingly accurate in addressing potential and identified risks.

Join the Pharmacovigilance Conference to discuss paths forward and formulate answers to key questions:

1. Benefit-risk assessment - What and how to do in practice?
2. What are the key pharmacovigilance inspection trends, plus options for improving organisation and processes - including the role of the EU QPPV and the Pharmacovigilance System Master File (PSMF)?
3. What progress and insights have been made within new EU project WEB-RADR on pharmacovigilance and social media?
4. What are the current regulatory and practical challenges of the Risk Management Plan and can potential improvements be identified?
5. How do the latest Pharmacoepidemiological approaches support risk management?

The conference format is designed to stimulate dialogue and generate solutions through a series of interactive sessions and workshops conducted in an informal setting allowing for in-depth discussion in smaller groups.

Day 1: Workshops dedicated to collaboration with experts and colleagues on benefit-risk assessment and differing approaches to the implementation of the regulation changes

Day 2 Morning: Interactive Presentations on Risk Management and Pharmacovigilance Plans

Day 2 Afternoon: Workshop on Risk Minimisation Measures, with several experts from industry, academia and regulatory authorities convening to discuss the current issues and propose different approaches.

WHAT YOU WILL LEARN

- How to assess benefit-risk in practice
- How to implement the new EV rules
- How to improve inspection outcomes
- How to manage signals with access to EV and, in the future, to social media
- Which pharmacoepidemiological methods are appropriate for supporting risk management
- How to evaluate the effectiveness of risk minimisation measures

WHO SHOULD ATTEND?

Established professionals who are seeking to improve practical skills in key areas in pharmacovigilance, including:

- Signal management
- Pharmacoepidemiology
- Risk Management Plan
- Benefit-risk assessment
- Quality assurance
# DAY ONE | WEDNESDAY, 10 MAY

| 08:00 | REGISTRATION AND WELCOME COFFEE |

## WORKSHOPS ON BENEFIT-RISK ASSESSMENT IN PRACTICE

Choose one of these Parallel Workshops

<table>
<thead>
<tr>
<th>09:00</th>
<th>SESSION 1A</th>
<th>SESSION 1B</th>
</tr>
</thead>
<tbody>
<tr>
<td>WORKSHOP ON BENEFIT-RISK ASSESSMENT IN PSUR: DISCUSSION ON PRACTICES</td>
<td>WORKSHOP ON BENEFIT-RISK KEY DRIVERS</td>
<td></td>
</tr>
<tr>
<td>Co-Leaders:</td>
<td>Co-Leaders:</td>
<td></td>
</tr>
<tr>
<td>Sarah Morgan, Benefit-Risk Management, Group Manager, MHRA, UK</td>
<td>Shahrul Mt-Isa, Associate Principal Scientist, Biostatistics, MSD, UK</td>
<td></td>
</tr>
<tr>
<td>Doris Stenver, PRAC Member, Chief Medical Officer, Danish Medicines Agency, Denmark</td>
<td>Kaatje Bollaerts, Biostatistician, IMI Coordinator, P-95, Belgium</td>
<td></td>
</tr>
</tbody>
</table>

In the PSUR it is expected to provide a practical evaluation of the benefit-risk of the medicinal product. This evaluation is frequently given in general terms. How could we improve and present this assessment taking into consideration a competent authority and PRAC expectations?

Depending on the medicinal product what would be the best key drivers to assess the benefit-risk and how should this assessment should be updated over time?

| 10:30 | COFFEE BREAK |

## WORKSHOPS ON EV ACCESS IMPLEMENTATION AND PSMF CHALLENGES

Choose one of these Parallel Workshops

<table>
<thead>
<tr>
<th>11:00</th>
<th>SESSION 2A</th>
<th>SESSION 2B</th>
</tr>
</thead>
<tbody>
<tr>
<td>WORKSHOP ON IMPLEMENTATION EXPERIENCE AND CHALLENGES AS EV ACCESS IS GAINED</td>
<td>WORKSHOP ON HOW TO OPTIMISE HAVING MULTIPLE PSMFS</td>
<td></td>
</tr>
<tr>
<td>Co-Leaders:</td>
<td>Co-Leaders:</td>
<td></td>
</tr>
<tr>
<td>Margaret Walters, Deputy EU Qualified Person for Pharmacovigilance, MSD, UK</td>
<td>Maria Wishart, Deputy EU Qualified Person for Pharmacovigilance, AstraZeneca, UK</td>
<td></td>
</tr>
<tr>
<td>Sabine Brosch, Principal Scientific Administrator, European Medicines Agency (EMA), EU</td>
<td>Dionne Usher, Senior Specialist, EU QPPV Office, MSD, UK</td>
<td></td>
</tr>
</tbody>
</table>

Based on examples of EudraVigilance (EV) readiness preparation to date, participants will take part in an interactive session aimed at identifying best practices and sharing potential solutions to practical challenges.

EU, non-EU, License Partner... just to name a few pharmacovigilance system master files (PSMFs) that we need to align, produce and track. How are companies approaching the increasing demand for PSMFs?

| 12:30 | LUNCH |

## WORKSHOPS WRAP-UP FOR DAY 1

Leader: Margaret Walters, Deputy EU Qualified Person for Pharmacovigilance, MSD, UK

Leaders, discussants and attendees from all 4 workshops will convene in one group to review, compare and discuss key learnings from the workshops.

- Benefit-Risk Assessment in PSUR: Discussion on Practices
- Benefit-Risk Key Drivers
- Implementation Experience and Challenges as EV Access is Gained
- How to Optimise Having Multiple PSMFs

| 15:30 | COFFEE BREAK |

## PHARMACOVIGILANCE AND SOCIAL MEDIA

Co-Chairs:

- Phil Tregunno, Signal Management Unit Manager, Medicines & Healthcare products Regulatory Agency (MHRA), UK
- Sabine Brosch, Principal Scientific Administrator, European Medicines Agency (EMA), EU

The session will discuss how social media can be used for pharmacovigilance system - what are the points to consider from a regulator perspective and what best practices have been identified until now?

| 17:30 | END OF DAY 1 |
09:00  SESSION 5

RISK MANAGEMENT PLAN: CHALLENGES AND OPPORTUNITIES
Co-chairs:
Doris Stenver, PRAC Member, Chief Medical Officer, Danish Medicines Agency, Denmark
Jan Petracek, CEO European Pharminvent Services, Czech Republic

The guidelines for risk management plans (RMPs) evolved over time but there are still some questions on the content and how to develop it. What are the expectations of the PRAC? How is it assessed by the authorities? What are the main weaknesses of the RMPs provided by the license holders and how to improve them?

RMP Experiences – A PRAC Perspective
Doris Stenver, PRAC Member, Chief Medical Officer, Danish Medicines Agency, Denmark

Lessons Learned from 100 EU-RMPs Submitted 2013-2017 - Will the New EU GVP Module V Help?
Jan Petracek, CEO European Pharminvent Services, Czech Republic

Practical Aspects of EU RMP for Generics
Olga Mariscal, EU QPPV, Cinfa, Spain

10:30  COFFEE BREAK

11:00  SESSION 6

PHARMACOEPIDEMIOLOGICAL STUDIES FOR PHARMACOVIGILANCE PLAN
Co-Chairs:
Katherine Donegan, Pharmacoepidemiology Research & Intelligence Unit Manager, Medicines & Healthcare products Regulatory Agency (MHRA), UK
Steve Hobbiger, Vice President and QPPV, R&D, GSK, UK

Studies proposed in a pharmacovigilance plan aim to characterise the main adverse drug reactions (ADRs) to be followed in the life cycle of medicinal products. With some examples, pros and cons of the methods to be used in pharmacovigilance plans will be presented.

Marianne Cunnington, Senior Director and Therapy Area Lead, GSK, UK

12:30  LUNCH

14:00  SESSION 7

WORKSHOP ON RISK MINIMISATION MEASURES AND EFFECTIVENESS EVALUATION
Co-Leaders:
Maarten Lagendijk, Pharmacovigilance Coordinator, Medicines Evaluation Board (MEB), Netherlands
Inge M. Zomerdijk, Pharmacovigilance Assessor, Medicines Evaluation Board (MEB), Netherlands

The 3-hour intensive workshop will look into detailed practices in risk minimisation and give insights to effectiveness evaluation from both regulator and industry perspective.

17:30  END OF CONFERENCE

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA. Speakers and agenda are subject to change without notice. Recording during DIA sessions is strictly prohibited without prior written consent from DIA.

Exhibition Opportunities
The Pharmacovigilance Workshop Series Conference & Exhibition offers the possibility to a limited number of company exhibition opportunities at this event. Showcase your product or service to a truly global audience of qualified professionals, from entry level to expert, in the pharmaceutical, biotechnology, devices and related healthcare industries, government, academia and healthcare delivery.

Exhibit Booths put you and your products directly in front of decision makers who are or can become your customers. For more information, or to sign up, contact: EMEA.Exhibition@DIAglobal.org
# Pharmacovigilance Conference | 10-11 May 2017 | Chelsea Harbour Hotel, London, UK

**REGISTRATION FORM**

**CATEGORY**

<table>
<thead>
<tr>
<th>Industry</th>
<th>€ 1'430.00</th>
<th>€ 1'585.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government/Charitable/Non-profit/Academia (Full-Time)</td>
<td>€ 715.00</td>
<td>€ 870.00</td>
</tr>
<tr>
<td>TUTORIAL: Introduction to the role of the QPPV - 09 May 2017</td>
<td>€ 400.00</td>
<td>€ 400.00</td>
</tr>
</tbody>
</table>

If DIA cannot verify your membership upon receipt of registration form, you will be charged the non-member fee. Group discount/SME rates available. Special rates for students and patient representatives on offer, subject to availability. Please contact DIA EMEA for more information.

Registration fee includes: refreshments, lunches, reception and meeting materials.

**TOTAL AMOUNT DUE: € ______________________**

*All fees are subject to the applicable VAT. Payment due 30 days after registration and must be paid in full by commencement of the event.

**ATTENDEE DETAILS**

Please complete in block capitals or make registration even simpler by attaching the attendee’s business card here.

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Company</th>
<th>Job Title</th>
<th>Address</th>
<th>Postal Code</th>
<th>City</th>
<th>Country</th>
<th>Telephone</th>
<th>Fax</th>
<th>Email</th>
</tr>
</thead>
</table>

Please provide your European VAT number

**PAYMENT METHODS**

- Credit cards: Payments by VISA, Mastercard or AMEX can be made by completing the details below. Please note that other types of credit card cannot be accepted.
  - Please charge my
  - VISA
  - MC
  - AMEX

- Bank transfers: When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the bank transfer. Payments in EURO should be addressed to “Account Holder: DIA.” Please include your name, company, Event ID#17108 as well as the invoice number to ensure correct allocation of your payment.

Payments must be net of all charges and bank charges must be borne by the payer. If you have not received your confirmation within five working days, please contact DIA Europe, Middle East and Africa.

By signing below, I confirm that I agree with DIA’s Terms and Conditions of booking. These are available from the office or online by clicking [here](#).

**TERMS AND CONDITIONS**

**Cancellations**

All cancellations must be made in writing and be received at the DIA Europe, Middle East and Africa office four weeks prior to the event start date. Cancellations are subject to an administrative fee:

- Industry (Member/Non-member) € 200.00
- Academia/Charitable/Government/Non-profit (Full-time) (Member/Non-member) € 100.00

For cancellations after this date, or if the delegate fails to attend the meeting, no refund of fees will be given and be responsible for the full registration fee.

DIA EMEA reserves the right to alter the venue and dates if necessary. If an event is cancelled, DIA EMEA is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for cancelling their own hotel and travel reservations.

**Transfer Policy**

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute attendees will be responsible for the non-member fee, if applicable. Please notify the DIA EMEA office of any such substitutions as soon as possible.

**Photography and Video Policy**

By attending the event, you give permission for images of you, captured during the conference through video, photo, and/or digital camera, to be used by DIA in promotional materials, publications, and website and waive any and all rights including but not limited to compensation or ownership.

The DIA Europe, Middle East & Africa Contact Center will be pleased to assist you with your registration from Monday to Friday between 08:00 and 17:00 CET.

Email emea@DIAglobal.org
Tel. +41 61 225 51 51
Fax +41 61 225 51 52
Web [www.DIAglobal.org](http://www.DIAglobal.org)
Mail DIA EMEA, Kuechengasse 16, 4051 Basel, Switzerland

© DIA 2017